Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Inferior vena cava filters reduce mortality in elderly patients with pulmonary embolism, cancer

16 Apr 2018

Elderly patients with pulmonary embolism and cancer seem to benefit from inferior vena cava filters, which reduce in-hospital and 3-month all-cause mortality, according to a study.

In-hospital all-cause mortality was lower among patients aged >60 years with vena cava filters than those without filters (7.4 percent vs 11.2 percent; relative risk [RR], 0.67; p<0.0001). Patients aged >60 years who received vena cava filters also had a lower all-cause mortality within 3 months compared with those who did not receive a filter (15.2 percent vs 17.4 percent; RR, 0.86; p<0.0001).

“Further investigation is needed, particularly in younger patients,” the investigators said.

Analysis was carried out using administrative data from the Premier Healthcare Database, 2010–2014, in patients hospitalized with pulmonary embolism and solid malignant tumours. The International Classification of Disease, Ninth Revision, Clinical Modification codes were used to identify patients.

“Administrative data have shown a lower mortality in hospitalized patients with pulmonary embolism and cancer who receive a vena cava filter. In the absence of a randomized controlled trial of vena cava filters in such patients, further investigation is necessary,” the investigators noted.

In a subgroup analysis of the same study, results showed that the additional use of an inferior vena cava filter reduced in-hospital mortality among stable patients with acute pulmonary embolism receiving thrombolytic therapy. [Am J Med 2018;131:97-99]

These findings support those of a 2012 study, which concluded that inferior vena cava filter is a safe and effective method for pulmonary thromboembolism prophylaxis, especially for patients with high bleeding risk and who cannot be anticoagulated. [Turk Neurosurg 2012;22:269-273]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.